Haemonetics Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026New board members bring fresh perspectives and expertise that can help guide company decisions and strategy.
How companies organize their business affects how investors understand which parts are profitable and growing.
The 10-K is the most detailed yearly report showing all financial results, assets, and risks investors need to know.
Earnings reports show whether a company made more or less money, helping you understand if the business is healthy.
Board changes matter because directors oversee company management and protect shareholder interests.
Paying off debt reduces financial obligations and shows the company has strong cash to meet its commitments.
Companies sharing responsibility reports show commitment to ethics, environment, and society alongside making profits.
Stocky reads Haemonetics Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Haemonetics Corporation's most recent tracked filing was a 8-K on 28 Jul 2026: Carlyle Group executive Martin Madaus joins board.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.